EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Serological and Molecular Diagnosis of Toxoplasmosis in Some Cancer Patients

Asan Muhannad Mohamed, Hiro Mohamed Obaid, Wafa Mahmood Jasim

Medical Journal of Babylon · 2026-01 · 23 (1) · 752-756

DOI: 10.4103/mjbl.mjbl_902_23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Journal of Babylon, online erschienen am 30.04.2026. Verfasst von Asan Muhannad Mohamed und 2 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Toxoplasma gondii , a parasite affecting both humans and animals globally, is an obligate intracellular protozoan. Immunosuppressed patients have a high prevalence of toxoplasma infection. For some immunocompromised individuals, such as those with autoimmune diseases, 90% of toxoplasmosis cases in immunocompromised people such as cancer patients are typically asymptomatic, with the remaining 10% displaying flu-like symptoms, ophthalmic illness, or cervical lymphadenopathy. Toxoplasmosis is severe and could be fatal.

Objective

The purpose of this study was to identify Immunoglobulin g (IgG) and Immunoglobulin m (IgM) antibodies and perform a molecular assay against toxoplasma in malignant patients to promptly refer the patients to a doctor for treatment. Materials and Methods: This case-control study was done on 7–75 years old cancer patients and was carried out on 70 cancer patients and 20 healthy controls obtained from Kirkuk Oncology and Hematology Center. Patients’ information was recorded before sampling. Blood samples were examined for various serological tests (latex agglutination test [LAT], rapid immuno-chromatographic test [RITC], and enzyme-linked immunosorbent assay [ELISA]) and molecular analysis (polymerase chain reaction).

Results

The findings indicate that an ELISA test revealed some subjects had toxoplasmosis infections in cancer patients—7 (10%) IgG+/IgM+, 11 (15.71%) IgG+/IgM−, 4 (5.71%) IgG−/IgM+, and 48 (68.58%) IgG−/IgM−. The seropositive rate of T. gondii in cancer patients, according to LAT, was 33 (47.1%), in RITC it was 34 (48.6%), and in ELISA test it was 22 (31.4%). Molecular result of the PCR showed 2 (4%) positives and 14 (28%) negatives.

Conclusions

Before, during, and after chemotherapy, patients must be tested for toxoplasmosis based on the frequency of positive cases in these patients.

Zitieren

APA

Mohamed, A. M., Obaid, H. M., & Jasim, W. M. (2026). Serological and Molecular Diagnosis of Toxoplasmosis in Some Cancer Patients. Medical Journal of Babylon, 23(1), 752-756. https://doi.org/10.4103/mjbl.mjbl_902_23

Vancouver

Mohamed AM, Obaid HM, Jasim WM. Serological and Molecular Diagnosis of Toxoplasmosis in Some Cancer Patients. Medical Journal of Babylon. 2026;23(1):752-756. doi:10.4103/mjbl.mjbl_902_23

BibTeX
@article{Mohamed2026,
  author = {Mohamed, Asan Muhannad and Obaid, Hiro Mohamed and Jasim, Wafa Mahmood},
  title = {Serological and Molecular Diagnosis of Toxoplasmosis in Some Cancer Patients},
  journal = {Medical Journal of Babylon},
  year = {2026},
  volume = {23},
  number = {1},
  pages = {752--756},
  doi = {10.4103/mjbl.mjbl_902_23}
}
Kostenlos starten →